SPS deal: Six questions growers need answered
© GNP Crop producers need answers to three practical questions from the proposed UK-EU sanitary and phytosanitary (SPS) agreement.
These are: which plant protection products (PPPs) they can buy, how long they can use them and whether they can market crops treated before the rules change.
The agreement promises easier trade, but bringing pesticide regulation back into alignment could seriously shake up existing pesticide authorisations, access to new chemistry and the workload facing manufacturers and regulators.
At the recent BCPC Congress in Harrogate and ahead of the UK-EU summit on Friday 20 November, Farmers Weekly looked at the key questions growers need answering this week.
See also: What to consider when planning a new pesticide store
1. Which crop protection tools will stay?
The first distinction is between newer substances approved in Great Britain ahead of the EU and older chemistry retained here after EU approval ended.
BASF’s Jonathan Howarth highlighted three newer GB-only active substances: cinmethylin, isoflucypram and pydiflumetofen.
CropLife UK chief executive Dave Bench hopes an arrangement allowing such substances to remain available while the EU completes its assessments will be put in place.
“My expectation is that some kind of carve-out will be created in the SPS deal that allows those to stay on the market until such time that the EU make their decision,” he told Farmers Weekly.
That remains an expectation, rather than a confirmed exemption. The outlook could differ for substances the EU has already decided not to renew.
Jonathan’s presentation included herbicides flufenacet and metribuzin, and fungicide penthiopyrad among examples of EU non-renewals.
Dave expects substances in this category to leave the GB market eventually, but said he did not know what withdrawal periods, if any, would apply.
A third group comprises substances renewed in the EU with changed conditions.
Alignment could require further assessment of GB products and their authorised uses, increasing the workload for regulators.
For growers, confirmation that an active substance remains approved will not answer every question.
The crucial detail is whether the particular product, crop, application timing and use on which their programme depends remain authorised, and this is a key watchpoint.
2. Will the transition fit a growing season?
The agreement’s start date is only part of the story – growers and agronomists also need clear deadlines for product sale, storage and use.
Jonathan illustrated why the supply chain cannot respond overnight. In his example, delivery of a pesticide product to a farmer took one day, but raw materials were ordered 18 months beforehand.
Active-substance manufacture began 12 months before delivery, product manufacture three months before and arrival in the UK one month before.
Those are illustrative timings, rather than a timetable for every pesticide, but they show how decisions taken well before an agreement starts can affect availability afterwards.
Manufacturers and distributors may already have committed to supplies intended for future seasons.
Growers will also have made cropping decisions around particular weed, pest and disease-control challenges and available solutions.
NFU senior regulatory affairs adviser Chris Hartfield stressed that the headline agreement and its implementation must be examined separately.
Implementation could “lessen or increase” the potential impact, he said.
The practical test is whether transition arrangements accommodate both the supply chain and a complete crop programme, rather than imposing deadlines that interrupt midway through.
3. What happens to crops already treated?
Permission to apply a pesticide and permission to market the resulting crop are related, but separate, issues.
Maximum residue levels (MRLs) set the permitted residue levels in food and feed.
Where GB and EU limits differ, alignment raises questions about produce treated legally before a change, but sold afterwards.
It’s thought that some 14,000 or more individual substance-commodity combinations have diverged between GB and EU since Brexit.
That matters particularly for crops held in store or supplied under contracts extending beyond implementation, and Jonathan called for protection for legally treated GB produce.
Growers and buyers will need to know which limits apply, when they change and how any transitional provisions cover crops already harvested or growing.
However, an MRL difference should not automatically be interpreted as a lost pesticide use or a blocked consignment.
His talk argued that most misalignments need not require use withdrawals, with analysis of the differences and regulatory co-operation offering possible solutions.
The question for growers and agronomists is specific: can a crop treated legally under the existing rules still be marketed when the new arrangements begin?
4. Could regulatory workload affect availability?
Even where an active substance survives alignment, the administrative changeover could matter for product availability.
Jonathan identified about 40 actives renewed in the EU since 2021 and hundreds of GB products containing EU-renewed substances.
These figures describe different things, as one active can underpin numerous products, each with its own authorisation requirements.
Dave warned that adopting accumulated EU renewal decisions together could create a surge of product-renewal work for both manufacturers and Health and Safety Executive’s Chemicals Regulation Division (HSE-CRD).
“Those periods are not doable for either the companies or CRD if all of the renewal decisions are adopted at implementation,” he said. His proposed remedy is a mechanism to phase that work.
Separate questions surround new substances already being assessed in GB.
Jonathan identified 13 ongoing evaluations listed on HSE’s website, while suggesting the total could be higher.
Industry wants clarity on whether these assessments will be completed and how the work could be used within the future system.
HSE-CRD’s Adrian Dixon said the regulator continues to operate under the current law until it changes.
Growers should look out for arrangements that prevent useful products becoming delayed or unavailable because assessments and authorisations cannot be processed through the changeover.
5. What benefits and influence will growers gain?
Easier trade is the central government objective. For crop protection, co-operation with the EU could also offer opportunities to reduce duplicated assessment work and improve access to products.
Defra deputy-director for pesticides policy, Helena Busby, told the conference that the UK would again become a rapporteur member state, contributing to the assessment of active substances.
That was a stated government position, although the practical arrangements are yet to be clarified in public.
A scientific assessment role should not be confused with EU membership or voting rights.
For growers, there is a need to understand how UK conditions and uses will be represented when decisions are shaped.
Similarly, discussion of mutual recognition and the EU authorisation system does not establish precisely which routes will become available.
The test is whether co-operation translates into timely access to useful products and proper consideration of GB farming needs.
6. Where will practical answers come from?
Growers should expect the detail to emerge progressively. Chris said the NFU would assess the agreement once public and communicate its implications through its usual channels.
Defra has outlined sector-specific guidance, testing with representative organisations, direct engagement and webinars.
CropLife also intends to publish its analysis and pursue unanswered questions. “We’re not going to keep that to ourselves,” Mr Bench said.
For now, a useful step is to identify with an agronomist which threatened products and uses underpin the coming seasons’ plans, especially in crops where alternatives are limited.
Suppliers and buyers can then help establish the implications of confirmed sale, use and residue deadlines.
GB-EU pesticide divergence: Three categories affected by SPS alignment |
||
|
Category |
Actives |
Main issue |
|
New GB approvals |
Cinmethylin, isoflucypram, pydiflumetofen, bixlozone, lupin extract and elemental iron. |
Whether existing GB-only approvals can remain in place while EU assessments are completed. |
|
EU non-renewed or unsupported actives retained in GB |
Flufenacet, metribuzin, penthiopyrad, benthiavalicarb, triflusulfuron-methyl and spirotetramat. |
Whether alignment removes access, and what transition, sale and use-up periods would apply. |
|
EU-renewed actives potentially requiring GB product reassessment |
Spinosad, pyrimethanil, pyraclostrobin, mecoprop-P, mepiquat, captan, folpet, trinexapac, metconazole, glyphosate and cyazofamid. |
How to manage renewal work for hundreds of GB products without disrupting availability. These are examples from about 40 EU-renewed actives, not new substances awaiting initial GB approval. |
| Source: Jonathan Howarth’s BCPC Congress presentation, November 2026. Selected examples as presented, not exhaustive lists | ||
SPS agreement: What growers should watch for
- Which pesticides and specific crop uses will remain authorised? Exemptions for newer GB-only chemistry are not yet confirmed.
- Will sale and use periods accommodate cropping plans and stocks already in the supply chain?
- Will residue rules protect the marketing of produce treated legally before changes, including crops in store?
- How will outstanding assessments and product renewals be managed without disrupting availability?
- Look for confirmed advice from Defra, the HSE, the NFU and suppliers. Summit headlines may precede operational detail.
- Identify essential products and uses with your agronomist, particularly where alternatives are limited.
